Aspire Biopharma Holdings (ASBP) Payables (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Payables for 6 consecutive years, with $972108.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables fell 63.77% year-over-year to $972108.0 in Q2 2026; TTM through Jun 2026 was $972108.0, a 63.77% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 33.08% from the prior year.
• Payables was $972108.0 for Q2 2026 at Aspire Biopharma Holdings, up from $857925.0 in the prior quarter.
• Over five years, Payables peaked at $4.6 million in Q3 2025 and troughed at $19067.0 in Q1 2022.
• A 5-year average of $965999.3 and a median of $509263.0 in 2024 frame the typical range for Payables.
• Across the five-year window, Payables surged 968.51% in 2023 and plunged 67.54% in 2026, its largest moves.
• Over 5 years, Payables stood at $180634.0 in 2022, then decreased by 8.99% to $164389.0 in 2023, then soared by 859.34% to $1.6 million in 2024, then sank by 33.08% to $1.1 million in 2025, then decreased by 7.89% to $972108.0 in 2026.
• The last three Payables figures came in at $972108.0 (Q2 2026), $857925.0 (Q1 2026), and $1.1 million (Q4 2025), per Business Quant data.